Michael O'Dwyer to Cyclophosphamide
This is a "connection" page, showing publications Michael O'Dwyer has written about Cyclophosphamide.
Connection Strength
0.081
-
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncoimmunology. 2021 01 25; 10(1):1859263.
Score: 0.045
-
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leuk Lymphoma. 2018 06; 59(6):1338-1347.
Score: 0.036